JP5859544B2 - カンナビノイド１受容体阻害剤としての新規化合物 - Google Patents

カンナビノイド１受容体阻害剤としての新規化合物 Download PDF

Info

Publication number
JP5859544B2
JP5859544B2 JP2013527016A JP2013527016A JP5859544B2 JP 5859544 B2 JP5859544 B2 JP 5859544B2 JP 2013527016 A JP2013527016 A JP 2013527016A JP 2013527016 A JP2013527016 A JP 2013527016A JP 5859544 B2 JP5859544 B2 JP 5859544B2
Authority
JP
Japan
Prior art keywords
pyrimidin
pyrazolo
methanol
pyrrolidin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013527016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536836A5 (https=
JP2013536836A (ja
Inventor
ソン ソク シン，
ソン ソク シン，
ヨン ドク ホン，
ヨン ドク ホン，
キョン フィ ビョン，
キョン フィ ビョン，
ミ ヨン パク，
ミ ヨン パク，
ジン キュ チョイ，
ジン キュ チョイ，
ヤン フィ パク，
ヤン フィ パク，
イル ホン ペ，
イル ホン ペ，
ヨン ヒョプ ジョ，
ヨン ヒョプ ジョ，
キョン ミン イム，
キョン ミン イム，
ヨン ホ パク，
ヨン ホ パク，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Publication of JP2013536836A publication Critical patent/JP2013536836A/ja
Publication of JP2013536836A5 publication Critical patent/JP2013536836A5/ja
Application granted granted Critical
Publication of JP5859544B2 publication Critical patent/JP5859544B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013527016A 2010-08-31 2011-08-31 カンナビノイド１受容体阻害剤としての新規化合物 Expired - Fee Related JP5859544B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20100085042 2010-08-31
KR10-2010-0085042 2010-08-31
PCT/KR2011/006474 WO2012030170A2 (ko) 2010-08-31 2011-08-31 카나비노이드 1 수용체 저해제로 작용하는 신규 화합물

Publications (3)

Publication Number Publication Date
JP2013536836A JP2013536836A (ja) 2013-09-26
JP2013536836A5 JP2013536836A5 (https=) 2014-10-16
JP5859544B2 true JP5859544B2 (ja) 2016-02-10

Family

ID=45773400

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527016A Expired - Fee Related JP5859544B2 (ja) 2010-08-31 2011-08-31 カンナビノイド１受容体阻害剤としての新規化合物

Country Status (6)

Country Link
US (1) US8975264B2 (https=)
EP (1) EP2617723A4 (https=)
JP (1) JP5859544B2 (https=)
KR (1) KR101914161B1 (https=)
CN (1) CN103153999B (https=)
WO (1) WO2012030170A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020531519A (ja) 2017-08-21 2020-11-05 ナビゲン，インコーポレーテッド Ａｒｆ６阻害剤及び関連する方法
CN109856394B (zh) * 2019-04-16 2022-04-19 浙江诺迦生物科技有限公司 一种基于细胞多巴胺释放效应的大麻素类活性物质的检测方法及其检测试剂盒
WO2020232350A1 (en) * 2019-05-15 2020-11-19 The Regents Of The University Of Colorado, A Body Corporate Assays for synthetic cannabinoids
CN112007156A (zh) * 2019-05-30 2020-12-01 复旦大学 大麻素受体药物在制备治疗心肌细胞坏死性凋亡药剂中的应用
CN112755189A (zh) * 2019-11-02 2021-05-07 复旦大学 1型大麻素受体拮抗剂在制备治疗心肌细胞焦亡药剂中的应用
TWI907472B (zh) * 2020-08-05 2025-12-11 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物
KR102912267B1 (ko) * 2023-04-20 2026-01-15 한국화학연구원 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
TW201345908A (zh) * 2006-07-05 2013-11-16 Mitsubishi Tanabe Pharma Corp 吡唑并〔１，５-ａ〕嘧啶化合物
AR061793A1 (es) * 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
CN101671336B (zh) * 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途

Also Published As

Publication number Publication date
KR20130099930A (ko) 2013-09-06
EP2617723A2 (en) 2013-07-24
EP2617723A4 (en) 2014-07-02
CN103153999A (zh) 2013-06-12
KR101914161B1 (ko) 2018-11-02
US20130158025A1 (en) 2013-06-20
WO2012030170A2 (ko) 2012-03-08
JP2013536836A (ja) 2013-09-26
CN103153999B (zh) 2016-06-01
WO2012030170A3 (ko) 2012-06-28
US8975264B2 (en) 2015-03-10

Similar Documents

Publication Publication Date Title
JP5859544B2 (ja) カンナビノイド１受容体阻害剤としての新規化合物
EP2694509B1 (en) Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases
EP3154979B1 (en) Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
EP4424311A2 (en) Pyrrolopyrimidines as cftr potentiators
CN101917849A (zh) Bcr-abl的小分子豆蔻酸酯抑制剂及其使用方法
EA031201B1 (ru) Соединения имидазопиридазина
AU2008231543B2 (en) Pyrimido [4, 5-D] azepine derivatives as 5-HT2C agonists
JP2018508542A (ja) Ｐｄｅ２阻害剤としてのトリアゾリルピリミジノン化合物
KR101494919B1 (ko) 2환식 복소환 화합물
JP2017122103A (ja) うつ病、糖尿病及びパーキンソン病のような幾つかの障害の処置において使用するためのｔａａｒ調節薬としてのピラゾールカルボキサミド誘導体
WO2019085894A1 (zh) 一类含氮稠环化合物及其制备方法和用途
JP2010540423A (ja) ピロロピリミジン化合物類
JP6074775B2 (ja) ピラゾロ［３，４−ｄ］ピリミジン化合物、その製造およびシグマリガンドとしての使用
CA3007595C (en) 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
JP2006519813A (ja) 置換された２−（ジアザ−ビシクロ−アルキル）−ピリミドン誘導体
WO2004113344A1 (ja) ピラゾロピリミジン化合物のメタンスルホン酸塩、その結晶およびその製造方法
WO2015155566A1 (en) Fused pyrazole compounds as cb1r antagonists and uses thereof
NZ615557B2 (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases
OA16607A (en) Pyrrolo [2, 3 -D] pyrimidine derivatives as inhibitors of tropomyosin- related kinases.
HK1141024A (en) Pyrimido [4,5-d] azepine derivatives as 5-ht2c agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151216

R150 Certificate of patent or registration of utility model

Ref document number: 5859544

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees